NASDAQ · CRSP
CRISPR Therapeutics AG
$54.26+$0.15 (+0.28%)
CRISPR Therapeutics AG’s quoted price sits in the lower half of its reported 52-week range, 17.76% below the high.
Loading market information…
NASDAQ · VOR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vor Biopharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vor Biopharma Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.82. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vor Biopharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 20, 2025 |
| -$8.80-2,488.24% vs estimate |
| $0.00 |
| Q3 2024 | Nov 7, 2024 | -$8.000.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $27.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$54.26+$0.15 (+0.28%)
CRISPR Therapeutics AG’s quoted price sits in the lower half of its reported 52-week range, 17.76% below the high.
$13.23-$0.09 (-0.68%)
Intellia Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.41% below the high.
$2.72+$0.09 (+3.42%)
Sana Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.99% below the high.
$2.93-$0.02 (-0.68%)
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
$1.58-$0.05 (-3.07%)
Autolus Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 38.76% below the high.
$2.54-$0.04 (-1.55%)
Rocket Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.39% below the high.
$1.46-$0.04 (-2.67%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.97% below the high.
$2.17$0.00 (0.0%)
Fate Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.82% below the high.
